Testing SHR-A1904 for Advanced Neuroendocrine Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called SHR-A1904 for patients with advanced neuroendocrine cancer (a rare type of cancer) who have already tried at least one round of chemotherapy. The goal is to see if this drug can slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced neuroendocrine carcinoma confirmed by a biopsy or tissue sample
- Your cancer has grown after at least one prior chemotherapy treatment (usually platinum-based)
- You are between 18 and 75 years old
- You have at least one measurable tumor that can be tracked on scans
- Your blood counts, liver, kidney, and heart function are within acceptable ranges
- You have a good overall health status and expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1904 for people with advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this drug can help shrink or control the cancer.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests two new drugs, SHR-A1921 and SHR-A2009, for people with advanced non-small cell lung cancer that has progressed after prior treatment with an antibody-drug conjugate. The goal is to see if these drugs can shrink tumors and help patients live longer.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
Hear when a new Advanced Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.